Bupropion is NOT an appropriate treatment for Intermittent Explosive Disorder
There is no evidence supporting the use of bupropion for IED, and the available evidence points to other medications as more effective options. While your patient meets the safety criteria for bupropion use (no seizure history, no eating disorder, not on MAOIs), this does not make it an appropriate choice for treating IED.
Evidence-Based Treatment Options for IED
The most recent systematic review of pharmacotherapy for impulse control disorders 1 identified oxcarbazepine and fluoxetine as the most efficacious treatments for IED based on randomized controlled trials. Notably, naltrexone was effective for kleptomania, another impulse control disorder, but bupropion was not studied or recommended for any impulse control disorder 1.
Why Not Bupropion?
- Zero evidence for IED: No randomized controlled trials have evaluated bupropion for IED treatment 2, 1
- Wrong mechanism: Bupropion is a dopamine/norepinephrine reuptake inhibitor 3 approved for depression and smoking cessation 4, not for impulse control or aggression
- Potential activation: Bupropion commonly causes nervousness, insomnia, and agitation 3, 5—symptoms that could theoretically worsen impulsive aggression in IED patients
Recommended Treatment Algorithm for IED
First-line pharmacotherapy:
- Fluoxetine (SSRI) - demonstrated efficacy in RCTs for IED 1
- Oxcarbazepine (anticonvulsant) - most efficacious in controlled trials 1
Important contraindication:
- Avoid divalproex - not superior to placebo and associated with significant adverse effects in IED patients 1
Critical Safety Considerations for Bupropion (If Ever Considered Off-Label)
While your patient lacks the absolute contraindications, the FDA label 4 and clinical evidence 6, 7, 6 establish clear warnings:
- Seizure risk: 0.1% at therapeutic doses up to 300 mg/day 8, with risk increasing dose-dependently 9
- Contraindicated in: Seizure disorders, eating disorders (bulimia/anorexia), concurrent MAOI use, uncontrolled hypertension 7, 10, 4
- Neuropsychiatric monitoring required: Black box warning for suicidal thoughts/behaviors, especially in patients under 24 years 4
Clinical Bottom Line
Prescribe fluoxetine or oxcarbazepine for IED based on the available RCT evidence 1. Bupropion lacks any supporting data for this indication and carries activation risks that could be counterproductive in a disorder characterized by impulsive aggression. The fact that your patient can safely receive bupropion does not make it an appropriate choice when evidence-based alternatives exist.